New allergy vaccine on track for pivotal trial phase

Privately-owned Austrian company Biomay has announced positive results from a Phase IIb study into its grass pollen allergy vaccine BM32.

BM32 is an investigational grass pollen allergy vaccine based on an innovative kind of technology which the company believes has the potential to create a “paradigm shift” in the treatment of allergies.

The immunotherapeutics specialists stated that the study reached its primary endpoint and showed that a regimen of five monthly injections of BM32 produced a clinically superior outcome to other dosing schemes.